Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  2. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  3. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  4. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  5. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  6. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  7. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  8. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  9. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  10. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  11. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  12. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  13. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  14. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  15. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  16. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  17. Han X, et al. 2022. Nutrients. 14:. PubMed
  18. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  19. Qin T, et al. 2023. Virol J. 20:75. PubMed
  20. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  21. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  22. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  23. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  24. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  25. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  26. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  27. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  28. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  29. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  30. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  31. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  32. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  33. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  34. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  35. Li ZX, et al. 2022. Arch Virol. :. PubMed
  36. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  37. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  38. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  39. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  40. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  41. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  42. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  43. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  44. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  45. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  46. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  47. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  48. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  49. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  50. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  51. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  52. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  53. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  54. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  55. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  56. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  57. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  58. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  59. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  60. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  61. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  62. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  63. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  64. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  65. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  66. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  67. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  68. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  69. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  70. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  71. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  72. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  74. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  75. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  76. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  77. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  78. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  79. Wan X, et al. 2018. Nature. 560:107. PubMed
  80. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  81. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  82. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  83. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  84. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  85. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  86. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  87. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  89. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  90. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  91. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  92. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  93. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  94. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  95. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  96. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  97. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  98. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  99. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  100. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  101. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  102. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  103. Kim M, et al. 2018. Immunity. 49:151. PubMed
  104. Papa I, et al. 2017. Nature. 547:318. PubMed
  105. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  106. Zhang J, et al. 2018. Nature. 553:91. PubMed
  107. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  108. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  109. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  110. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  111. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  112. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  113. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  114. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  115. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  116. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  117. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  118. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  119. Wang X, et al. 2022. Elife. 11:. PubMed
  120. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  121. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  122. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  123. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  124. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  125. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  126. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  127. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  128. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  129. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  130. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  131. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  132. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  133. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  134. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  135. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  136. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  137. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312712 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account